19.88
price up icon13.41%   2.35
pre-market  Pre-mercato:  20.38   0.50   +2.52%
loading

Beam Therapeutics Inc Borsa (BEAM) Ultime notizie

pulisher
Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 17, 2025

BEAM Therapeutics’ SWOT analysis: base editing pioneer’s stock faces pivotal year - Investing.com

Jun 17, 2025
pulisher
Jun 16, 2025

H.C. Wainwright reiterates buy rating on Beam Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 16, 2025
pulisher
Jun 16, 2025

H.C. Wainwright reiterates buy rating on Beam Therapeutics stock - Investing.com

Jun 16, 2025
pulisher
Jun 14, 2025

Cathie Wood’s ARK ETFs adjust holdings, buying GitLab and Beam Therapeutics stock - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clini - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics (BEAM) Reports Strong Results for Sickle Cell Therapy - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Beam reports positive results from sickle cell disease treatment - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics reports positive data from sickle cell therapy trial - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics reports positive data from sickle cell therapy trial By Investing.com - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics (BEAM) Releases Promising Data from BEACON Trial | BEAM Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

New Clinical Data: BEAM's Sickle Cell Gene Therapy Achieves Remarkable 60%+ Success Metric in All Patients - Stock Titan

Jun 13, 2025
pulisher
Jun 11, 2025

Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

ARK Investment Acquires 349K Shares of Beam Therapeutics (BEAM) | BEAM Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Tesla’s Driverless Robotaxis Are Operating On Texas Streets - The Globe and Mail

Jun 11, 2025
pulisher
Jun 06, 2025

Beam Therapeutics Confirms Key Decisions at Annual Meeting - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Beam Therapeutics Announces Pricing of Underwritten Offering - Revista ADVFN

Jun 06, 2025
pulisher
Jun 05, 2025

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com

Jun 05, 2025
pulisher
Jun 04, 2025

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - The Globe and Mail

Jun 04, 2025
pulisher
Jun 04, 2025

BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates - The Globe and Mail

Jun 04, 2025
pulisher
Jun 03, 2025

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR - mx.advfn.com

Jun 03, 2025
pulisher
Jun 03, 2025

Beam gets FDA orphan drug status for sickle cell disease treatment - Seeking Alpha

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Says Potential Sickle Cell Therapy Receives FDA Orphan Drug Designation - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics (BEAM) Gains FDA Orphan Drug Status for Sickle - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics’ BEAM-101 receives FDA orphan drug status for SCD treatment - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Gra - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Announces Orphan Drug Designation For BEAM-101 - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - Yahoo Finance

Jun 03, 2025
pulisher
Jun 01, 2025

Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io

Jun 01, 2025
pulisher
May 31, 2025

Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com

May 31, 2025
pulisher
May 30, 2025

Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 29, 2025

FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)’ AATD Gene Therapy - Insider Monkey

May 29, 2025
pulisher
May 29, 2025

Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment - Investing.com India

May 29, 2025
pulisher
May 29, 2025

FDA Grants Orphan Drug Status to Beam Therapeutics' (BEAM) BEAM-302 | BEAM Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Beam receives Orphan Drug status for genetic disorder asset BEAM-302 - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Beam Therapeutics Scores Dual FDA Wins as Orphan Drug Status Follows Promising AATD Trial Results - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Beam Therapeutics: A Cautious Hold On A Base Editing Pioneer (NASDAQ:BEAM) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Shareholders May Find It Hard To Justify Increasing Beam Therapeutics Inc.'s (NASDAQ:BEAM) CEO Compensation For Now - simplywall.st

May 29, 2025
pulisher
May 28, 2025

Beam Therapeutics (BEAM) Secures FDA Orphan Designation for New - GuruFocus

May 28, 2025
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):